Anti-Romiplostim (Nplate) ELISA Kit

Catalog No.

KAD76501

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative sandwich enzyme immunoassay technique. Romiplostim has been pre-coated onto a microplate. Samples or standards are pipetted into microwells and anti-Romiplostim will be captured by immobilized Romiplostim. After washing away any unbound substances, a biotin-labeled Romiplostim is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Anti-Romiplostim bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Anti-Romiplostim concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

31.25 - 2,000 ng/mL

Sensitivity

17.08 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	848.7	206.8	46.8	888.7	225.1	53.9
Standard deviation	24.6	9.6	4.3	34.7	13.0	2.8
CV (%)	2.9	4.7	9.1	3.9	5.8	5.2

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

High-dose romiplostim for donor-type aplasia., PMID:40504447

Efficacy and safety of romiplostim and eltrombopag in management of thrombocytopenia in Wiskott-Aldrich syndrome patients., PMID:40400288

THPO promoter mutation: a familial study on congenital amegakaryocytic thrombocytopenia., PMID:40386912

The 'Stop TPO-RA in ITP Patients' study: Clinical and immune modulatory effects of romiplostim tapering., PMID:40384450

Systemic Lupus Erythematosus with Refractory Immune Thrombocytopenia Progressing to Catastrophic Anti-Phospholipid Syndrome During Thrombopoietin Receptor Agonist Therapy: A Case Report., PMID:40364121

A case with a novel GATA1 variant mimicking immune thrombocytopenia attacks., PMID:40323132

Robotic Splenectomy as a Salvage Therapy Post Failed Splenic Embolization in Chronic Immune Thrombocytopenic Purpura Due to the COVID-19 Vaccine., PMID:40314051

Utility and Safety of Romiplostim as an Alternative to Platelet Transfusion for Neonates., PMID:40302050

The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK., PMID:40276091

Efficacy and safety and analysis of thrombopoietin receptor agonists for the treatment of immune thrombocytopenia in adults: analysis of a systematic review and network meta-analysis of randomized controlled trials and results of real-world safety data., PMID:40196346

Prolonged Cytopenia with CAR-T Cell Therapy and Management Recommendations., PMID:40161263

Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA., PMID:40101243

A multicenter mixed-methods study on the effects of intermittent fasting in patients with immune thrombocytopenia receiving thrombopoietin receptor agonists., PMID:40098741

[Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag]., PMID:40044178

Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment., PMID:40040262

Romiplostim in Aplastic Anemia: A Single-Center Retrospective Study., PMID:40027000

Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: a pharmacovigilance study based on the FDA Adverse Event Reporting System., PMID:40016824

Avatrombopag for the Treatment of Immune Thrombocytopenia., PMID:39905676

Sustained response off treatment after fostamatinib in refractory immune thrombocytopenia: A series of four case reports., PMID:39894785

Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy., PMID:39880098

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia., PMID:39852180

Romiplostim Reduces Platelet Transfusion Needs in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation., PMID:39840153

Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia - Case Report., PMID:39802214

Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies., PMID:39780402

Optimization of Romiplostim Biosimilar Efficacy Trial Using In Silico Clinical Trial Approach for Patients With Immune Thrombocytopenia., PMID:39702972

Mitani K, Lee JW, Jang JH, et al. Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study. Blood Adv. 2024;8(6):1415-1419., PMID:39625711

Role of Serum Interleukin-10 and Interleukin-27 Levels in the Prognosis of Immune Thrombocytopenia in Iraqi Children., PMID:39582823

Romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed immune thrombocytopenia: A pilot study., PMID:39581951

The Establishment of a Novel Murine Model of Immune Thrombocytopenia in Pregnancy and the Impacts of Thrombopoietin Receptor Agonist on Platelet Production., PMID:39539867

[Pharmacotherapy for aplastic anemia]., PMID:39505555

A second chance for avatrombopag in chemotherapy-induced thrombocytopenia., PMID:39491815

Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)., PMID:39394928

[New drugs for the treatment of primary immune thrombocytopenia]., PMID:39358266

Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies., PMID:39348667

Long-term safety and effectiveness of romiplostim for chronic idiopathic thrombocytopenic purpura in real-world settings., PMID:39342544

Expansion effect of romiplostim on hematopoietic stem and progenitor cells versus thrombopoietin and eltrombopag., PMID:39302624

Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review., PMID:39290805

Ruptured Ovarian Cyst Leading to Massive Spontaneous Intraperitoneal Hemorrhage in Chronic Immune Thrombocytopenic Purpura (ITP): Successful Nonsurgical Intervention., PMID:39280513

Is there a role for eltrombopag drug levels in paediatric immune thrombocytopenia management?, PMID:39228082

Cost-utility analysis of romiplostim for the treatment of chronic primary immune thrombocytopenia in China., PMID:39220274

Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report., PMID:39175509

Tapering and Sustained Remission of Thrombopoietin Receptor Agonists (TPO-RAs): Is it Time for Paediatric ITP?, PMID:39162982

Peptibodies: Bridging the gap between peptides and antibodies., PMID:39142490

Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature., PMID:39135303

Idiopathic Thrombocytopenic Purpura (ITP) Complicated by a Hemorrhagic Ovarian Cyst and Hemoperitoneum: A Case Report., PMID:39130867

Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management., PMID:39105265

Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway., PMID:39102877

Romiplostim use in immune thrombocytopenia: Experience in Cuenca, Ecuador., PMID:39079145

Document Download

Anti-Romiplostim (Nplate) ELISA Kit.pdf